A study from the UK and Canada followed more than 2500 patients with Barrett’s Esophagus for an average of 9 years, and divided them into two groups: Nexium 20 mg a day and Nexium 40 mg twice a day. The high dose group had fewer numbers of esophageal cancer or High Grade Dysplasia (a precursor of cancer) than the low dose group. There were no adverse effects from either dose of long term Nexium. Lancet, Aug 2018.
